Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn Henry

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|July 14, 2016
The pathway to clinical use of a cancer biomarkerN Lynn Henry
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Endocrine therapy toxicity: management optionsN Lynn Henry
The Lancet. Oncology|December 15, 2024
Optimising therapy and avoiding overtreatment in breast cancerN Lynn Henry
Pain Management|March 21, 2014
Aromatase inhibitor-associated musculoskeletal pain: taking 'AIM' at a symptom in breast cancer survivorsN Lynn Henry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Reply to K.I. PritchardN Lynn Henry, Vered Stearns
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2015
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerAki Morikawa, N Lynn Henry
Breast Cancer Research and Treatment|October 14, 2010
One size does not fit all: quality of life during adjuvant aromatase inhibitor therapyN Lynn Henry, Vered Stearns
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Treatment-emergent effects may predict benefit from endocrine therapyN Lynn Henry, Vered Stearns
Future Oncology (London, England)|November 24, 2017
Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancerRobert Havard, N Lynn Henry
Molecular Oncology|February 24, 2012
Cancer biomarkersN Lynn Henry, Daniel F Hayes
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|July 14, 2016
The pathway to clinical use of a cancer biomarkerN Lynn Henry
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Endocrine therapy toxicity: management optionsN Lynn Henry
The Lancet. Oncology|December 15, 2024
Optimising therapy and avoiding overtreatment in breast cancerN Lynn Henry
Pain Management|March 21, 2014
Aromatase inhibitor-associated musculoskeletal pain: taking 'AIM' at a symptom in breast cancer survivorsN Lynn Henry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Reply to K.I. PritchardN Lynn Henry, Vered Stearns
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2015
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerAki Morikawa, N Lynn Henry
Breast Cancer Research and Treatment|October 14, 2010
One size does not fit all: quality of life during adjuvant aromatase inhibitor therapyN Lynn Henry, Vered Stearns
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Treatment-emergent effects may predict benefit from endocrine therapyN Lynn Henry, Vered Stearns
Future Oncology (London, England)|November 24, 2017
Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancerRobert Havard, N Lynn Henry
Molecular Oncology|February 24, 2012
Cancer biomarkersN Lynn Henry, Daniel F Hayes
Pageof 20